Drug discovery for chagas disease should consider Trypanosoma cruzi strain diversity

Memorias do Instituto Oswaldo Cruz

Volumn 109, Issue 6, 2014, Pages 828-833

  Zingales, Bianca ^a   Miles, Michael A ^b   Moraes, Carolina B ^c   Luquetti, Alejandro ^d   Guhl, Felipe ^e   Schijman, Alejandro G ^f   Ribeiro, Isabela ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^d FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^e UNIVERSIDAD DE LOS ANDES   (Colombia)

^f INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^g Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

Guidelines; In vitro drug screening; T. cruzi genetic diversity

Indexed keywords

TRYPANOSOMA CRUZI;

ANTITRYPANOSOMAL AGENT;

BIODIVERSITY; CHAGAS DISEASE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; LIFE CYCLE STAGE; NEGLECTED DISEASES; PARASITOLOGY; SPECIES DIFFERENCE; TRYPANOSOMA CRUZI;

BIODIVERSITY; CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; LIFE CYCLE STAGES; NEGLECTED DISEASES; SPECIES SPECIFICITY; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84907201083     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276140156     Document Type: Article

References (31)

1. Aquilino C, Gonzalez ML, Seco EM, Escudero L, Corvo L, Soto M, Fresno M, Malpartida F, Bonay P 2012. Differential trypanocidal activity of novel macrolide antibiotics; correlation to genetic lineage. PLoS ONE 7: e40901.
2. Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira L, Caldera AR, Payares G, Sanoja C, Burgos JM, Leon-Rossell A, Concepcion JL, Schijman AG, Levin M, Oldfield E, Urbina JA 2006. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 49: 892-899.
3. Buckner FS 2011. Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Adv Parasitol 75: 89-119.
4. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40: 2592-2597.
5. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL 2013. New, combined and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis 209: 150-162.
6. Bustamante JM, Tarleton RL 2011. Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov 6: 653-661.
7. Canavaci AM, Bustamante JM, Padilla AM, Brandan CMP, Simpson LJ, Xu D, Boehlke CL, Tarleton RL 2010. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis 4: e740.
8. Cura CI, Mejia-Jaramillo AM, Duffy T, Burgos JM, Rodriguero M, Cardinal MV, Kjos S, Gurgel-Gonçalves R, Blanchet D, de Pablos LM, Tomasini N, Silva A, Russomando G, Cuba CA, Aznar C, Abate T, Levin MJ, Osuna A, Gürtler RE, Diosque P, Solari A, Triana-Chávez O, Schijman AJ 2010. Trypanosoma cruzi I genotypes in different geographical regions and transmission cycles based on a microsatellite motif of the intergenic spacer of spliced leader genes. Int J Parasitol 40: 1599-1607.
9. Diniz LF, Urbina JA, de Andrade IM, Mazzeti AL, Martins TAF, Caldas IS, Talvani A, Ribeiro I, Bahia MT 2013. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 7: e2367.
10. DNDi-Drugs for Neglected Diseases initiative 2013. Proof of concept study of E1224 to treat adults patients with Chagas disease. Available from: clinicaltrials.gov/ct2/show/NCT01489228?term=chagas+disease&rank=9.
11. Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, Doyle PS 2010. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas disease. Antimicrob Agents Chemother 54: 3326-3334.
12. Filardi LS, Brener Z 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81: 755-759.
13. Guhl F, Ramírez JD 2011. Trypanosoma cruzi I diversity: towards the need of genetic subdivision? Acta Trop 119: 1-4.
14. Lewis MD, Fortes FA, Taylor MC, Burrell-Saward H, McLatchie AP, Miles MA, Kelly JM 2014. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol doi: 10.1111/cmi.12297.
15. Lewis MD, Llewellyn MS, Gaunt MW, Yeo M, Carrasco HJ, Miles MA 2009. Flow cytometric analysis and microsatellite genotyping reveal extensive DNA content variation in Trypanosoma cruzi populations and expose contrasts between natural and experimental hybrids. Int J Parasitol 39: 1305-1317.
16. Miles MA, Llewellyn MS, Lewis MD, Yeo M, Baleela R, Fitzpatrick S, Gaunt MW, Mauricio IL 2009. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future. Parasitology 136: 1509-1528.
17. Molina I, Prat JG, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valério L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A 2014. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med 370: 1899-1908.
18. Moraes CB, Giardini M, Kim H, Franco CH, Araujo-Junior AM, Schenkman S, Chatelain E, Freitas-Junior LH 2014. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep 4 doi: 10.1038/srep04703.
19. Neal RA, van Bueren J 1988. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. Trans R Soc Trop Med Hyg 82: 709-714.
20. Nohara LL, Lema C, Bader JO, Aguilera RJ, Almeida IC 2010. High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi. Parasitol Int 59: 565-570.
21. Rassi Jr A, Rassi A, de Rezende JM 2012. American trypanosomiasis (Chagas disease). Infect Dis Clin N Am 26: 275-291.
22. Schijman AG, Bisio A, Orellana L, Sued M, Duffy T, Mejia-Jaramillo AM, Cura C, Auter F, Veron V, Qvarnstrom Y, Deborggraeve S, Hijar G, Zulantay I, Lucero RH, Velazquez E, Tellez T, Leon ZS, Galvão L, Nolder D, Rumi MM, Levi JE, Ramirez JD, Zorrilla P, Flores M, Jercic MI, Crisante G, Añez N, de Castro AM, Gonzalez CI, Viana KA, Yachelini P, Torrico F, Robello C, Diosque P, Chavez OT, Aznar C, Russomando G, Büscher P, Assal A, Guhl F, Sosa-Estani S, da Silva A, Britto C, Luquetti A, Ladzins J 2010. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 5: e931.
23. Schofield CJ, Jannin J, Salvatella R 2006. The future of Chagas disease control. Trends Parasitol 22: 583-588.
24. Sosa-Estani S, Viotti R, Segura EL 2009. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104 (Supplement I): 167-180.
25. Tibayrenc M 1998. Genetic epidemiology of parasitic protozoa and other infectious agents: the need for an integrated approach. Int J Parasitol 28: 85-104.
26. Urbina JA 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55-68.
27. Vago AR, Andrade LO, Leite AA, Reis DD, Macedo AM, Adad SJ, Tostes S, Moreira MC, Filho GB, Pena SD 2000. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol 156: 1805-1809.
28. WHO-World Health Organization 2012. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. Available from: apps.who.int/iris/bitstream/10665/77472/1/WHO_TRS_975_eng.pdf.
29. WHO-World Health Organization 2013. Chagas disease (American trypanosomiasis). Available from: who.int/mediacentre/factsheets/fs340/en/.
30. Zingales B, Andrade SG, Briones MRS, Campbell DA, Chiari E, Fernandes O, Guhl F, Lages-Silva E, Macedo AM, Machado CR, Miles MA, Romanha AJ, Sturm NR, Tibayrenc M, Schijman AG 2009. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 104: 1051-1054.
31. Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MMG, Schijman AG, Llewelly MS, Lages-Silva E, Machado CR, Andrade SG, Sturm NR 2012. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol 12: 240-253.